| Original language | English (US) |
|---|---|
| Pages (from-to) | 13 |
| Number of pages | 1 |
| Journal | CNS spectrums |
| Volume | 4 |
| Issue number | 7 |
| DOIs |
|
| State | Published - 1999 |
| Externally published | Yes |
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Advances in the treatment of depression. / Hollander, E.
In: CNS spectrums, Vol. 4, No. 7, 1999, p. 13.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Advances in the treatment of depression
AU - Hollander, E.
N1 - Funding Information: This work was supported by the National Institutes of Health (NIH)/National Institute of Mental Health (P50 MH 058922, R01 MH 042088, and U19 MH 069056) (to C.B.N.) and by the Emory Mentored Clinical Research Scholars Program through a grant from NIH/National Center for Research Resources (K12 RR 017643) (to P.E.H.). Funding Information: Disclosures: C.B.N. has received grants from the American Foundation for Suicide Prevention (AFSP); AstraZeneca; Bristol-Myers-Squibb; Forest Laboratories; Janssen Pharmaceutica; National Alliance for Research in Schizophrenia and Depression (NARSAD); National Institute of Mental Health (NIMH); Pfizer Pharmaceuticals; Stanley Foundation; National Alliance for the Mentally Ill (NAMI); and Wyeth-Ayerst. He is a consultant for Abbott Laboratories, Acadia Pharmaceuticals, Bristol-Myers-Squibb, Corcept, Cypress Biosciences, Cyberonics, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Otsuka, Pfizer Pharmaceuticals, Quintiles, and Wyeth-Ayerst. He is on the Speakers Bureau for Abbott Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, and Pfizer Pharmaceuticals. He owns stock in Corcept, Cypress Biosciences, and Acadia Pharmaceuticals. He is on the Board of Directors for AFSP, American Psychiatric Institute for Research and Education (APIRE), George West Mental Health Foundation, Novadel Pharma, and National Foundation for Mental Health (NFMH). He has patents for “Method and devices for transdermal delivery of lithium (US 6375,990 B1)” and “Method to estimate serotonin and norepinephrine transporter occupancy after drug treatment using patient or animal serum (provisional filing April 2001).” He has equity in Reevax, BMC-JR LLC, and CeNeRx. P.E.H. has received grants from the American Federation for Aging Research (AFAR), Neuronetics, Inc., and the National Center for Research Resources.
PY - 1999
Y1 - 1999
UR - http://www.scopus.com/inward/record.url?scp=0032792906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032792906&partnerID=8YFLogxK
U2 - 10.1017/s1092852900011962
DO - 10.1017/s1092852900011962
M3 - Comment/debate
AN - SCOPUS:0032792906
VL - 4
SP - 13
JO - CNS Spectrums
JF - CNS Spectrums
SN - 1092-8529
IS - 7
ER -